Aikaterini Anagnostou, MD, PhD
- Texas Medical Center
Director, Food Immunotherapy Program
Texas Children's Hospital
Associate Professor of Pediatric Allergy, Baylor College of Medicine
|Aristotle University, Greece||medical school||Doctor of Medicine||2000|
|London School of Pediatrics and Child Health||residency||Pediatrics||2008|
|University of Cambridge, UK||PhD||Doctor of Philosophy||2012|
|London School of Pediatrics and Child Health||fellowship||Pediatric Allergy & Immunology||2015|
As Director of the Food Immunotherapy Program, Dr. Anagnostou is passionate about investigating new and innovative treatments for food allergy. She obtained her PhD from Cambridge University in the United Kingdom and her dissertation focused on two separate trials of Peanut Oral Immunotherapy in children. Her research work was published in The Lancet and received international recognition.
Dr. Anagnostou has developed a strong interest in preventing and treating all forms of allergic disease. She is committed to improving the quality of life of allergic patients and their families.
Dr. Anagnostou studied Medicine at Aristotle University and graduated with First Class Honors in 2000. She trained in Pediatrics at Addenbrooke’s Hospital, Cambridge and at Great Ormond Street Hospital and the Royal Brompton Hospital, London. Prior to her appointment as Associate Professor at Texas Children’s Hospital, she worked as a Pediatric Allergist in the Children’s Allergy Unit at St Thomas’ Hospital in London.
View News Articles:
|American Academy of Allergy, Asthma and Immunology (AAAAI)||Fellow|
|American College of Allergy, Asthma and Immunology (ACAAI)||Fellow|
|British Society of Allergy and Clinical Immunology (BSACI)||Member|
|European Acedemy of Allergy and Clinical Immunology (EAACI)||Member|
|Royal College of Paediatrics and Child Health (RCPCH)||Member|
Anagnostou K, Islam S, King Y, Foley L,Pasea L, Bond S, Palmer C, Deighton J,Ewan P, Clark A. Assessing the efficacy of oral immunotherapy for the desensitization of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.
The Lancet 2014 Apr 12;383(9925):1297-304.